Clinical Trial Update: A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating Pasritamig (JNJ-78278343) in combination with JNJ-86974680 for prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• JNJ-86974680
• Pasritamig

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostatic Neoplasms | Phase 1 | Status: RECRUITING